We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Endo (ENDP) Settles Disputes with Federal Trade Commission
Read MoreHide Full Article
Endo International plc announced that it has resolved all disputes with the U.S. Federal Trade Commission (FTC).
Shares of Endo have underperformed the Zacks classified Medical-Drugs industry in the past one year. Specifically, the stock plunged 79.0% during this period, in comparison to a decline of 1.7% for the industry.
Coming back to the latest news, both Endo and the FTC have filed a joint motion in the U.S. District Court for the Northern District of California, seeking the entry of a ten-year Stipulated Order for Permanent Injunction.
This order resolves all disputes between the FTC and Endo relating to the patent infringement settlements entered by Endo pertaining to Opana ER and Lidoderm products. In addition, the order also resolves the FTC's claims against Endo's subsidiary Par Pharmaceutical Companies, Inc.
We remind investors that FTC first asserted claims against Endo and certain generics manufacturers relating to the Opana ER and Lidoderm patent settlements in Mar 2016. The FTC alleged that certain aspects of the Opana ER and Lidoderm settlements constituted unfair methods of competition in violation of federal law and sought injunctive and declaratory relief, as well as other remedies including restitution and disgorgement. The complaint was filed in the U.S. District Court for the Eastern District of Pennsylvania.
Thereafter, the FTC voluntarily dismissed its lawsuit in Oct 2016 but stated its intention to refile elsewhere.
As per the Stipulated Order, Endo is not required to make any monetary payment to the FTC and will dismiss its claims in the declaratory judgment actions. The FTC has agreed that the prior dismissal of its claims against Endo in the U.S. District Court for the Eastern District of Pennsylvania will be treated as void. The FTC will not file any other claims against Endo related to the Opana ER and Lidoderm settlements.
Endo has also agreed to certain covenants relating to the future settlement of patent infringement litigation for a period of 10 years.
Endo currently carries a Zacks Rank #4 (Sell). We note that shares are under tremendous pressure due to concerns related to the ongoing investigations and the present focus on drug pricing. Concerns relating to pricing are expected to remain a major overhang on the company’s shares. Moreover, estimates have gone down lately ahead of the company’s fourth-quarter 2016 earnings results.
Some better-ranked stocks in the health care sector include Enzo Biochem, Inc. (ENZ - Free Report) , Sunesis Pharmaceuticals, Inc. and Anika Therapeutics Inc. (ANIK - Free Report) . While Sunesis and Anika sports a Zacks Rank #1 (Strong Buy), Enzo Biochem carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss estimates for 2017 narrowed 5.88% over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 22.50%. Its share price was up 47.9% in the past one year.
Sunesis’ loss estimates narrowed 5.06% and 8.80% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.1%. Its share price was up 37.2% in the past one year.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Endo (ENDP) Settles Disputes with Federal Trade Commission
Endo International plc announced that it has resolved all disputes with the U.S. Federal Trade Commission (FTC).
Shares of Endo have underperformed the Zacks classified Medical-Drugs industry in the past one year. Specifically, the stock plunged 79.0% during this period, in comparison to a decline of 1.7% for the industry.
Coming back to the latest news, both Endo and the FTC have filed a joint motion in the U.S. District Court for the Northern District of California, seeking the entry of a ten-year Stipulated Order for Permanent Injunction.
This order resolves all disputes between the FTC and Endo relating to the patent infringement settlements entered by Endo pertaining to Opana ER and Lidoderm products. In addition, the order also resolves the FTC's claims against Endo's subsidiary Par Pharmaceutical Companies, Inc.
We remind investors that FTC first asserted claims against Endo and certain generics manufacturers relating to the Opana ER and Lidoderm patent settlements in Mar 2016. The FTC alleged that certain aspects of the Opana ER and Lidoderm settlements constituted unfair methods of competition in violation of federal law and sought injunctive and declaratory relief, as well as other remedies including restitution and disgorgement. The complaint was filed in the U.S. District Court for the Eastern District of Pennsylvania.
Thereafter, the FTC voluntarily dismissed its lawsuit in Oct 2016 but stated its intention to refile elsewhere.
As per the Stipulated Order, Endo is not required to make any monetary payment to the FTC and will dismiss its claims in the declaratory judgment actions. The FTC has agreed that the prior dismissal of its claims against Endo in the U.S. District Court for the Eastern District of Pennsylvania will be treated as void. The FTC will not file any other claims against Endo related to the Opana ER and Lidoderm settlements.
Endo has also agreed to certain covenants relating to the future settlement of patent infringement litigation for a period of 10 years.
Endo currently carries a Zacks Rank #4 (Sell). We note that shares are under tremendous pressure due to concerns related to the ongoing investigations and the present focus on drug pricing. Concerns relating to pricing are expected to remain a major overhang on the company’s shares. Moreover, estimates have gone down lately ahead of the company’s fourth-quarter 2016 earnings results.
Endo International PLC Price and Consensus
Endo International PLC Price and Consensus | Endo International PLC Quote
Key Picks in the Sector
Some better-ranked stocks in the health care sector include Enzo Biochem, Inc. (ENZ - Free Report) , Sunesis Pharmaceuticals, Inc. and Anika Therapeutics Inc. (ANIK - Free Report) . While Sunesis and Anika sports a Zacks Rank #1 (Strong Buy), Enzo Biochem carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss estimates for 2017 narrowed 5.88% over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 22.50%. Its share price was up 47.9% in the past one year.
Sunesis’ loss estimates narrowed 5.06% and 8.80% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.1%. Its share price was up 37.2% in the past one year.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>